CN1509183A - 蛋白酶体抑制剂在治疗干眼疾病中的用途 - Google Patents

蛋白酶体抑制剂在治疗干眼疾病中的用途 Download PDF

Info

Publication number
CN1509183A
CN1509183A CNA028098544A CN02809854A CN1509183A CN 1509183 A CN1509183 A CN 1509183A CN A028098544 A CNA028098544 A CN A028098544A CN 02809854 A CN02809854 A CN 02809854A CN 1509183 A CN1509183 A CN 1509183A
Authority
CN
China
Prior art keywords
group
alkyl
dry eye
formula
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028098544A
Other languages
English (en)
Chinese (zh)
Inventor
P��G������ķ��
P·G·克利姆科
�����ձ���
M·R·赫勒贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN1509183A publication Critical patent/CN1509183A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA028098544A 2001-05-21 2002-05-17 蛋白酶体抑制剂在治疗干眼疾病中的用途 Pending CN1509183A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29272201P 2001-05-21 2001-05-21
US60/292,722 2001-05-21

Publications (1)

Publication Number Publication Date
CN1509183A true CN1509183A (zh) 2004-06-30

Family

ID=23125916

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028098544A Pending CN1509183A (zh) 2001-05-21 2002-05-17 蛋白酶体抑制剂在治疗干眼疾病中的用途

Country Status (17)

Country Link
US (1) US6740674B2 (enExample)
EP (1) EP1392355B1 (enExample)
JP (1) JP2004530699A (enExample)
CN (1) CN1509183A (enExample)
AT (1) ATE353667T1 (enExample)
AU (1) AU2002308760B2 (enExample)
BR (1) BR0209883A (enExample)
CA (1) CA2447909C (enExample)
CY (1) CY1107531T1 (enExample)
DE (1) DE60218153T2 (enExample)
DK (1) DK1392355T3 (enExample)
ES (1) ES2278049T3 (enExample)
MX (1) MXPA03010634A (enExample)
PL (1) PL367287A1 (enExample)
PT (1) PT1392355E (enExample)
WO (1) WO2002094311A1 (enExample)
ZA (1) ZA200308768B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099687A2 (en) * 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
KR101434522B1 (ko) * 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
US7691852B2 (en) 2006-06-19 2010-04-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
RS54847B2 (sr) 2007-10-04 2019-09-30 Onyx Therapeutics Inc Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto-epoksida
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
WO2011136905A2 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
CN103893742B (zh) * 2014-03-03 2016-01-20 中山大学中山眼科中心 含卵黄膜外层蛋白1在制备治疗干眼药物中的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ES2084722T3 (es) 1990-05-29 1996-05-16 Boston Ocular Res Composicion para tratamiento del ojo seco.
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US6107289A (en) 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5958912A (en) 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
ATE185697T1 (de) 1992-04-21 1999-11-15 Schepens Eye Res Inst Androgentherapie am auge beim sjögrensyndrom
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
JPH1036289A (ja) 1996-07-24 1998-02-10 Sumitomo Pharmaceut Co Ltd 神経細胞の変性または死滅抑制剤
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
CA2281224A1 (en) 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
JP2001517631A (ja) 1997-09-25 2001-10-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤
CA2219867A1 (en) 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
WO2000003705A1 (en) 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
US6096733A (en) 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
EP1166781A4 (en) 1999-01-20 2002-08-21 Kyowa Hakko Kogyo Kk proteasome
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
ATE270268T1 (de) 1999-04-27 2004-07-15 Novartis Pharma Gmbh 2,4-diamino-3-hydroxycarboxylsäurederivate als proteasome inhibitoren

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途

Also Published As

Publication number Publication date
EP1392355A1 (en) 2004-03-03
AU2002308760B2 (en) 2006-05-11
MXPA03010634A (es) 2004-03-09
DK1392355T3 (da) 2007-04-30
DE60218153D1 (de) 2007-03-29
ATE353667T1 (de) 2007-03-15
DE60218153T2 (de) 2007-06-28
WO2002094311A1 (en) 2002-11-28
US6740674B2 (en) 2004-05-25
CA2447909C (en) 2011-04-05
CY1107531T1 (el) 2013-03-13
BR0209883A (pt) 2004-06-08
US20030008910A1 (en) 2003-01-09
ZA200308768B (en) 2005-01-26
PL367287A1 (en) 2005-02-21
EP1392355B1 (en) 2007-02-14
ES2278049T3 (es) 2007-08-01
JP2004530699A (ja) 2004-10-07
CA2447909A1 (en) 2002-11-28
PT1392355E (pt) 2007-03-30

Similar Documents

Publication Publication Date Title
CN1509183A (zh) 蛋白酶体抑制剂在治疗干眼疾病中的用途
ZA200502119B (en) Use of cytokine synthesis inhibitors for the tratment of dry eye disorders
DE60008143T2 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
CN1387505A (zh) 含羟基二十碳四烯酸衍生物的组合物和用于治疗干眼病的方法
AU2002308760A1 (en) Use of proteasome inhibitors to treat dry eye disorders
CN1387503A (zh) 羟基二十碳四烯酸盐,用于治疗干眼病的组合物和方法
CN1564683A (zh) 抗炎类固醇和muc－1促分泌素结合治疗干眼病的方法
CN1382046A (zh) 15－羟基二十碳四烯酸的插入杂原子的类似物和使用方法
CN1387502A (zh) 15－羟基二十碳四烯酸相关性化合物和使用方法
US7112588B2 (en) Use of proteasome inhibitors to treat dry eye disorders
CN1387504A (zh) ω－链改性的15－羟基二十碳四烯酸衍生物和它们用于治疗干眼病的方法
EP1393277B1 (en) USE OF NF-Kappa-B INHIBITORS TO TREAT DRY EYE DISORDERS
US7060728B2 (en) 11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
US20030109488A1 (en) Methods for treating dry eye
AU2002309963A1 (en) Use of NF-KAPPA-B inhibitors to treat dry eye disorders
WO2002034246A2 (en) Use of hydroperoxyeicosatetraenoic acid derivatives following refractive surgery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication